Please wait while the formulary information is being retrieved.
BIVALIRUDIN (BIVALIRUDIN)
- Prevent thrombosis in PCI in HIT
- PCI adjunct for thrombosis prevention
- Thrombosis w/heparin-induced thrombocytopenia during PCI
250 mg intravenous powder for solution
- Dosage information is not available
250 mg intravenous solution
- Dosage information is not available
- None
Contraindicated
- abciximab
- Activase
- Aggrastat In Sodium Chloride
- alteplase
- Cathflo Activase
- Coumadin
- dalteparin (porcine)
- Elmiron
- enoxaparin
- eptifibatide
- Fragmin
- heparin (porcine)
- heparin (porcine) in D5W
- heparin(porcine) in 0.45% NaCl
- heparin, porcine (PF)
- Integrilin
- Jantoven
- Lovenox
- pentosan polysulfate sodium
- Reopro
- Retavase
- reteplase
- tenecteplase
- tirofiban-0.9% sodium chloride
- Tnkase
- warfarin
Severe
Moderate
- None
- Deep peripheral nerve block
- Deep plexus block
- Hemorrhage
- Increased risk of bleeding
- Invasive procedure on spine
- Neuraxial anesthesia
- Placement of indwelling epidural catheter
Contraindicated
- None
Severe
Moderate
- None
BIVALIRUDIN (BIVALIRUDIN)
- Prevent thrombosis in PCI in HIT
- PCI adjunct for thrombosis prevention
- Thrombosis w/heparin-induced thrombocytopenia during PCI
- Hemorrhage
- Hypotension
- Back pain
- Dyspepsia
- Headache disorder
- Injection site sequelae
- Pain
- Pelvic pain
- Urinary retention
- Vomiting
More Frequent
Severe
Less Severe
- Bradycardia
- Hypertension
- Acute abdominal pain
- Insomnia
- Nausea
- Nervousness
- Symptoms of anxiety
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Bacterial sepsis
- Cerebral ischemia
- Fever
- Infection
- Intracranial bleeding
- Oliguria
- Pericardial tamponade
- Pulmonary edema
- Pulmonary hemorrhage
- Renal failure
- Retroperitoneal hemorrhage
- Thrombocytopenic disorder
- Thrombotic disorder
- Ventricular fibrillation
Less Severe
- Acute confusion
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Bivalirudin
No safety and efficacy established in pediatrics.
- 1 Day – 18 Years
- No safety and efficacy established in pediatrics.
Bivalirudin
- Severity Level:
2
- Additional Notes: Insufficient human data available; animal data suggest no developmental toxicity
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Bivalirudin
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Bivalirudin
General-In studies of patients undergoing PCI, 44% were >64 years of age and 12% of patients were >74 years old. Elderly patients experienced more bleeding events than younger patients.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Prevent thrombosis in PCI in HIT | |
| D75.82 | Heparin induced thrombocytopenia (HIt) |
| Thrombosis w/heparin-induced thrombocytopenia during PCI | |
| D75.82 | Heparin induced thrombocytopenia (HIt) |
| 0-9 | A-Z |
|---|---|
| D75.82 | Heparin induced thrombocytopenia (HIt) |
| D75.82 | Heparin induced thrombocytopenia (HIt) |
Formulary Reference Tool